Compare CHRW & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHRW | ILMN |
|---|---|---|
| Founded | 1905 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 19.0B |
| IPO Year | 1997 | 2000 |
| Metric | CHRW | ILMN |
|---|---|---|
| Price | $167.79 | $124.65 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 17 |
| Target Price | ★ $174.53 | $124.24 |
| AVG Volume (30 Days) | 1.5M | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | 25.13 | ★ 170.87 |
| EPS | 4.83 | ★ 5.45 |
| Revenue | ★ $14,869,380,000.00 | $4,343,000,000.00 |
| Revenue This Year | $4.33 | $6.54 |
| Revenue Next Year | $6.54 | $5.49 |
| P/E Ratio | $35.18 | ★ $23.16 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $84.68 | $68.70 |
| 52 Week High | $203.34 | $155.53 |
| Indicator | CHRW | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 49.06 |
| Support Level | $148.27 | $124.27 |
| Resistance Level | $167.90 | $126.00 |
| Average True Range (ATR) | 5.23 | 4.43 |
| MACD | -0.67 | 0.75 |
| Stochastic Oscillator | 11.46 | 68.47 |
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.